BIDOLI, PAOLO
 Distribuzione geografica
Continente #
NA - Nord America 6.624
EU - Europa 2.235
AS - Asia 831
AF - Africa 7
OC - Oceania 3
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.705
Nazione #
US - Stati Uniti d'America 6.525
IE - Irlanda 607
IT - Italia 472
SE - Svezia 392
CN - Cina 377
DE - Germania 362
HK - Hong Kong 298
GB - Regno Unito 114
CA - Canada 95
UA - Ucraina 91
IN - India 50
FI - Finlandia 42
VN - Vietnam 40
DK - Danimarca 37
AT - Austria 35
TR - Turchia 25
RU - Federazione Russa 22
FR - Francia 20
BE - Belgio 17
JP - Giappone 10
SG - Singapore 9
IR - Iran 8
NL - Olanda 8
PL - Polonia 7
MU - Mauritius 4
KR - Corea 3
AM - Armenia 2
AU - Australia 2
BD - Bangladesh 2
BG - Bulgaria 2
BR - Brasile 2
ES - Italia 2
EU - Europa 2
ID - Indonesia 2
MX - Messico 2
RO - Romania 2
SA - Arabia Saudita 2
TW - Taiwan 2
CL - Cile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GR - Grecia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PR - Porto Rico 1
SC - Seychelles 1
SI - Slovenia 1
Totale 9.705
Città #
Ann Arbor 1.331
Fairfield 850
Dublin 599
Ashburn 553
Woodbridge 481
Wilmington 430
Seattle 383
Chandler 372
Cambridge 320
Houston 318
Hong Kong 288
Frankfurt am Main 264
Princeton 248
New York 245
Jacksonville 163
Altamura 122
Lawrence 118
Beijing 98
Milan 87
Shanghai 74
San Diego 70
Dearborn 63
Toronto 46
Andover 44
Vienna 33
Nanjing 31
London 29
Guangzhou 28
Helsinki 27
Ottawa 25
Turin 25
Hangzhou 24
Falls Church 23
Dong Ket 22
Washington 22
Pune 20
Norwalk 18
Brussels 17
Hebei 13
Redmond 13
Rome 13
Jinan 12
Lachine 12
Tianjin 12
Torre Del Greco 12
Tappahannock 10
Zhengzhou 10
Chicago 8
Perugia 8
Edmonton 7
Fremont 7
Lissone 7
Nanchang 7
Kilburn 6
Kowloon 6
Mountain View 6
Shenyang 6
Singapore 6
Torino 6
Carignano 5
Genoa 5
Lodz 5
Mumbai 5
Ningbo 5
Phoenix 5
Prescot 5
San Mateo 5
Bari 4
Desio 4
Hefei 4
Jiaxing 4
Kunming 4
Laurel 4
New Bedfont 4
Tokyo 4
Wuhan 4
Bergamo 3
Bologna 3
Bonndorf 3
Broni 3
Camogli 3
Huizen 3
Kocaeli 3
Los Angeles 3
Montréal 3
Munich 3
Sacramento 3
Seoul 3
Seregno 3
Aci Catena 2
Acton 2
Amsterdam 2
Annone di Brianza 2
Atlanta 2
Bedford 2
Boardman 2
Central District 2
Changsha 2
Como 2
Giugliano in Campania 2
Totale 8.235
Nome #
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 273
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 237
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 234
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 223
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 222
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 213
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 212
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 208
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 168
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 168
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 163
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 159
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 159
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 157
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 153
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 149
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 148
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 134
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 130
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 127
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 127
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 127
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 118
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 117
When progressive dysphagia could be related to an “old friend” – a case report 114
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 114
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 113
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 109
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 106
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 102
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 94
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 94
Novel cytotoxic chemotherapies in small cell lung carcinoma 90
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 87
Drugs ten years later: epirubicin 86
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 84
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 83
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 82
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 82
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 82
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 78
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 78
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 77
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 75
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 75
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 74
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 73
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 72
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 71
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 70
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 69
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 69
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 69
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 69
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 69
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 68
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 68
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 68
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 68
Focus on nivolumab in NSCLC 66
Oxaliplatin doublets in non-small cell lung cancer: A literature review 65
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 64
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 63
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 62
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 62
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 61
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 61
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 61
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 61
Pilot study with adriamycin and ifosfamide in small cell lung cancer 61
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 59
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 57
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 57
Esophageal carcinoma: radiochemotherapy 56
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 56
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 56
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 56
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 55
Combined radiation and chemotherapy in esophageal cancer 55
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 55
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 55
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC) 54
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial 54
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial 53
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 53
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 52
Isolated cardiac metastasis from squamous cell esophageal cancer 52
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 52
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients 52
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 52
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) 51
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 51
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma 51
Radiologic examination in assessing the response to chemoradiotherapy of esophageal spinocellular carcinoma 51
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 51
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 50
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial 50
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 50
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX 49
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial 49
Totale 9.289
Categoria #
all - tutte 38.559
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.559


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019182 0 0 0 0 0 0 0 0 0 59 58 65
2019/20202.157 73 47 39 45 62 101 135 681 406 252 236 80
2020/20212.579 132 136 324 240 137 185 293 324 219 220 179 190
2021/20221.233 107 156 159 71 40 86 79 62 67 53 96 257
2022/20231.894 273 635 127 134 83 303 33 99 131 21 30 25
2023/20241.645 32 36 59 59 272 498 377 101 205 6 0 0
Totale 10.310